跳至主要内容
临床试验/NCT02703064
NCT02703064已完成不适用

To Study the Efficacy and Safety of Furocyst in Poly Cystic Ovary Syndrome Patients (PCOS)

Chemical Resources2 个研究点 分布在 1 个国家目标入组 107 人开始时间: 2015年3月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
107
试验地点
2
主要终点
Reduction in Overian volume & Number of overian Cysts

研究概览

简要总结

Poly cystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting approximately 5%-10% of all females worldwide . PCOS is a hormonal disorder that involves multiple organ systems within the body. Its cardinal features are Hyperandrogenism and polycystic ovary (PCO) morphology. Women with PCOS may complains about irregular menstrual periods or heavy menstrual bleeding, infertility, excessive growth of coarse facial and body hair, obesity, oiliness of the skin, seborrhea, and cystic acne.

详细描述

The symptoms of PCOS are anovulation, resulting in irregular menstruation (amenorrhea and oligomenorrhea) ovulation-related infertility, and polycystic ovaries, often associated with obesity, Type 2 diabetes, and high cholesterol levels. The level of serum insulin and insulin resistance are higher in women with PCOS (Hyperinsulinemia).Insulin resistance, defined as the decreased insulin mediated glucose utilization it is more common in women with PCOS up to 50 % in both obese and non obese women . It has also been recognized that some women with this syndrome will have PCO without clinical evidence of androgen excess, but will display evidence of ovarian dysfunction .

It is believed to be that, the Hyperinsulinemia of PCOS stimulates the androgens production and increase the activity by decreasing the sex hormone binding globulin (SHBG) thus increasing the free active testosterone level and by the activating the cytochrome P 450 C 17 alpha enzymatic system that controls androgens production.

The diagnosis of PCOS is based on Hyperandrogenism and chronic anovulation in the absence of specific pituitary or adrenal disease , and have disrupted ovulatory function with chronic oligomenorrhea (cycle length > 35 day) or amenorrhea (cycle length > 12 week) and typical appearance of polycystic ovaries by ultrasound according to the criteria of the Rotterdam consensus meeting 2003 for diagnosis of PCOS. The different diagnostic tests needed to adequately assess for the possibility of PCOS e.g. Pregnancy test, TSH level (for Hyperthyroidism), Prolactin test (for Hyperprolactinemia), Total testosterone (for ovarian tumor) and some tests forevaluating the insulin resistance syndrome in women: Waist circumference (>88 cm), Triglycerides (>150 mg/dL), HDL Cholesterol (<50 mg/dL), Blood pressure (>130/85) and Fasting glucose (>110 mg/dL). Fasting glucose- to- insulin ratio and 2 hour oral glucose tolerance test (2h- OGTT 140 - 199 mg/dL) may be better predictor of insulin resistance .

The management of the PCOS is symptoms specific e.g.

  1. Oral contraceptives, periodic progesterone withdrawal for the control of irregular menstruation.
  2. Oral contraceptives, Metformin and anti-androgens (Spironolactone) for the

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Premenopausal women between 18-45 years of age and BMI less than 42
  • Diagnosed with PCOS by Rottadom Criteria
  • Adequate hepatic, renal, Cardiac and hematological functions.
  • Patients willing to Participate and give informed consent in writing as well as in audio-visual form for the study.
  • Stable weight for last two months (Change of weight<3kg)

排除标准

  • Post menopausal women
  • Women with hysterectomy
  • Hyperprolactinemia
  • Patients with congenital adrenal hyperplasia
  • Patients suffering from Cushing's syndrome
  • Acute or chronic Medical illness including Hepatic, Cardiac or renal insufficiency, COPD,Gastrointestinal Disorders
  • Uncontrolled Hypertensive or known Diabetics on drugs
  • Use of oral contraceptives or HRT for last three months
  • Smoking or drug addicts or with psychiatric illness
  • Patients diagnosed with androgen secreting tumors.
  • Patients with thyroid dysfunction (T3, T4 level is higher than that in normal women of reproductive age)
  • Patients with Hypo-gonadotropic and Hypo-gonadism (central origin of ovarian dysfunction)
  • Pregnant or lactating mothers

研究组 & 干预措施

Furocyst

Experimental

Furocyst 500mg capsule, BD

干预措施: Furocyst (Dietary Supplement)

结局指标

主要结局

Reduction in Overian volume & Number of overian Cysts

时间窗: 12 weeks

次要结局

  • Restoration of normal menstrual cycle(12 weeks)

研究者

发起方
Chemical Resources
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验